Performance of Common Genetic Variants in Breast-cancer Risk Models
暂无分享,去创建一个
M. Thun | S. Chanock | M. García-Closas | P. Hartge | R. Hoover | D. Hunter | C. Kooperberg | M. Gail | B. Rosner | R. Prentice | P. Kraft | G. Thomas | S. Hankinson | K. Jacobs | D. Cox | S. Wacholder | C. Berg | H. Feigelson | M. Sherman | L. Brinton | J. Lissowska | W. R. Diver | R. Chlebowski | R. Jackson | D. Buckman | Peter Hui | R. Pfeiffer | Kaiser Permanente | W. Ryan Diver | R. Jackson | David G. Cox | W. Diver | France Lyon | D. Cox | D. Hunter | G. Thomas | David G. Cox | R. Pfeiffer | Denver | Biostatistics | P. Address | Spencer Feigelson | Genetics | G.-C | H. S. F. Inserm | Biostatistics | In Boston | Poland | Silver W B Spring | C. Berg | R. Jackson
[1] J. Tukey. One Degree of Freedom for Non-Additivity , 1949 .
[2] W. Willett,et al. Moderate alcohol consumption and the risk of breast cancer. , 1987, The New England journal of medicine.
[3] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[4] J. Benichou,et al. Epidemiology and Biostatistics Program of the National Cancer Institute , 1994 .
[5] J Benichou,et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.
[6] M H Gail,et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.
[7] J. Gohagan,et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. , 2000, Controlled clinical trials.
[8] Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer. , 2000, Journal of the National Cancer Institute.
[9] Carmen Rodriguez,et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort , 2002, Cancer.
[10] R. Langer,et al. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. , 2003, Annals of epidemiology.
[11] M. Thun,et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort , 2002, Cancer.
[12] Jinbo Chen,et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. , 2006, Journal of the National Cancer Institute.
[13] N. Chatterjee,et al. Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. , 2006, American journal of human genetics.
[14] S. Chanock,et al. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses , 2006, Human Genetics.
[15] W. Willett,et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.
[16] Lester L. Peters,et al. Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.
[17] Jose Jeronimo,et al. Human papillomavirus and cervical cancer , 2007, The Lancet.
[18] Francis S Collins,et al. A HapMap harvest of insights into the genetics of common disease. , 2008, The Journal of clinical investigation.
[19] M. Gail. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. , 2008, Journal of the National Cancer Institute.
[20] Olle Melander,et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. , 2008, The New England journal of medicine.
[21] B. Ponder,et al. Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.
[22] R. Wilkins. Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.
[23] Peter Almgren,et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2008, The New England journal of medicine.
[24] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[25] K. Narayan,et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2009, The New England journal of medicine.
[26] Gynecologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. , 2009, Obstetrics and gynecology.
[27] Timothy J Wilt,et al. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.
[28] S. Wacholder,et al. Risk estimation for the next generation of prevention programmes for cervical cancer. , 2009, The Lancet. Oncology.
[29] M. Thun,et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 , 2009, Nature Genetics.
[30] M. Gail. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. , 2009, Journal of the National Cancer Institute.
[31] W. Willett,et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.
[32] Peter Kraft,et al. Beyond odds ratios — communicating disease risk based on genetic profiles , 2009, Nature Reviews Genetics.
[33] W. Willett,et al. A genome-wide association study identifies alleles in FGFR 2 associated with risk of sporadic postmenopausal breast cancer , 2012 .